These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29858866)

  • 41. Use of noninsulin antidiabetic medications in hospitalized patients.
    Kopecky C
    Crit Care Nurs Clin North Am; 2013 Mar; 25(1):39-53. PubMed ID: 23410645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral combination therapy in primary care.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
    Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
    Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent trends in the use of antidiabetic medications from 2008 to 2013: A nation-wide population-based study from Taiwan.
    Ou HT; Chang KC; Liu YM; Wu JS
    J Diabetes; 2017 Mar; 9(3):256-266. PubMed ID: 27062145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative adherence to diabetes drugs: An analysis of electronic health records and claims data.
    Flory J; Gerhard T; Stempniewicz N; Keating S; Rowan CG
    Diabetes Obes Metab; 2017 Aug; 19(8):1184-1187. PubMed ID: 28266807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases.
    Lu Q; Li X; Liu J; Sun X; Rousselle T; Ren D; Tong N; Li J
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30710062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of diabetes drugs on the skeleton.
    Meier C; Schwartz AV; Egger A; Lecka-Czernik B
    Bone; 2016 Jan; 82():93-100. PubMed ID: 25913633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
    Frandsen CS; Dejgaard TF; Madsbad S
    Lancet Diabetes Endocrinol; 2016 Sep; 4(9):766-780. PubMed ID: 26969516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Updates on cardiovascular outcome trials in diabetes.
    Schnell O; Rydén L; Standl E; Ceriello A;
    Cardiovasc Diabetol; 2017 Oct; 16(1):128. PubMed ID: 29020969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.